Hypothyroidism Is a Predictive Factor for Better Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Undergoing Lenvatinib Therapy

SIMPLE SUMMARY: Patients with advanced hepatocellular carcinoma (HCC) undergoing molecular targeted therapy often experience non-negligible adverse events (AEs). Paradoxically, certain AEs are reportedly associated with a good prognosis. We aimed to identify factors predictive of treatment duration...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancers (Basel)
Hlavní autoři: Shomura, Masako, Okabe, Haruka, Sato, Emi, Fukai, Kota, Shiraishi, Koichi, Hirose, Shunji, Tsuruya, Kota, Arase, Yoshitaka, Anzai, Kazuya, Kagawa, Tatehiro
Médium: Artigo
Jazyk:Inglês
Vydáno: MDPI 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7690372/
https://ncbi.nlm.nih.gov/pubmed/33105621
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12113078
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky